Summary
IMNN Chart
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript
Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript
Imunon, Inc. ( IMNN ) Q3 2025 Earnings Call November 13, 2025 11:00 AM EST Company Participants Stacy Lindborg - President, CEO & Director Douglas V. Faller - Chief Medical Officer Kimberly Graper - CFO and Principal Financial & Accounting Officer Khursheed Anwer - Executive VP & Chief Scientific Officer Conference Call Participants David Bautz - Zacks Small-Cap Research James Molloy - Alliance Global Partners, Research Division Emily Bodnar - H.C.
Imunon, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 348,330 | $1.26M | $675,760.2 | -$580,521.12 | -46.21% |
 Joseph Gentili Riverview Capital Advisers LLC | 34,364 | $176,287.32 | $68,040.72 | -$108,246.6 | -61.4% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 5 | $26 | $9 | -$17 | -65.38% |
Imunon, Inc. (IMNN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Imunon, Inc. ever had a stock split?
Imunon, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Stacy R. Lindborg CEO | NASDAQ (CM) Exchange | 15117N701 CUSIP |
| US Country | 25 Employees | - Last Dividend | 7 Aug 2025 Last Split | - IPO Date |
Overview
Imunon, Inc. is a clinical stage biotechnology entity, originally named Celsion Corporation before altering its name in September 2022. Founded in 1982 and headquartered in Lawrenceville, New Jersey, the company embarks on the path of innovating healthcare through DNA-based immunotherapies, vaccines, and directed chemotherapies. With a strong focus on addressing cancer through groundbreaking methodologies, Imunon, Inc. steps forward into the biotechnological arena, aiming to revolutionize the treatment landscape for various cancer indications and potentially other diseases amenable to DNA-based treatments.
Products and Services
- GEN-1 Immunotherapy:
GEN-1 represents a pioneering approach in the realm of DNA-based immunotherapies, specifically targeting the localized treatment of ovarian cancer. This product underscores Imunon, Inc.'s commitment to advancing cancer treatment options through innovative DNA technology, focusing on enhancing the immune system’s capability to combat cancer.
- ThermoDox:
A proprietary heat-activated liposomal encapsulation of doxorubicin, ThermoDox is at the forefront of Imunon, Inc.'s development stage products. It is designed to target various cancer indications by utilizing a unique activation mechanism, where heat triggers the targeted release of doxorubicin directly at the tumor site. This method holds the promise of maximizing therapeutic effects while minimizing systemic side effects.
- Nucleic Acid-Based Platform Technologies:
Imunon, Inc. is also exploring two feasibility stage platform technologies focused on the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. These platforms represent the company’s forward-thinking approach in leveraging genetic information and technology to combat cancer and potentially other diseases through more personalized and targeted therapeutic strategies.
